| Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections J Li, RL Nation, JD Turnidge, RW Milne, K Coulthard, CR Rayner, ... The Lancet infectious diseases 6 (9), 589-601, 2006 | 1662 | 2006 |
| Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review AP Zavascki, LZ Goldani, J Li, RL Nation Journal of antimicrobial chemotherapy 60 (6), 1206-1215, 2007 | 1010 | 2007 |
| Colistin Resistance in Acinetobacter baumannii Is Mediated by Complete Loss of Lipopolysaccharide Production JH Moffatt, M Harper, P Harrison, JDF Hale, E Vinogradov, T Seemann, ... Antimicrobial agents and chemotherapy 54 (12), 4971-4977, 2010 | 921 | 2010 |
| Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various … SM Garonzik, J Li, V Thamlikitkul, DL Paterson, S Shoham, J Jacob, ... Antimicrobial agents and chemotherapy 55 (7), 3284-3294, 2011 | 844 | 2011 |
| Structure− activity relationships of polymyxin antibiotics T Velkov, PE Thompson, RL Nation, J Li Journal of medicinal chemistry 53 (5), 1898-1916, 2010 | 815 | 2010 |
| Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria J Li, RL Nation, RW Milne, JD Turnidge, K Coulthard International journal of antimicrobial agents 25 (1), 11-25, 2005 | 762 | 2005 |
| Heteroresistance to Colistin in Multidrug-Resistant Acinetobacter baumannii J Li, CR Rayner, RL Nation, RJ Owen, D Spelman, KE Tan, L Liolios Antimicrobial agents and chemotherapy 50 (9), 2946-2950, 2006 | 731 | 2006 |
| International consensus guidelines for the optimal use of the polymyxins: endorsed by the American college of clinical pharmacy (ACCP), European society of clinical … BT Tsuji, JM Pogue, AP Zavascki, M Paul, GL Daikos, A Forrest, ... Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 39 (1 …, 2019 | 718 | 2019 |
| Colistin in the 21st century RL Nation, J Li Current opinion in infectious diseases 22 (6), 535-543, 2009 | 566 | 2009 |
| Pharmacology of polymyxins: new insights into an ‘old’class of antibiotics T Velkov, KD Roberts, RL Nation, PE Thompson, J Li Future microbiology 8 (6), 711-724, 2013 | 554 | 2013 |
| Colistin Methanesulfonate Is an Inactive Prodrug of Colistin against Pseudomonas aeruginosa PJ Bergen, J Li, CR Rayner, RL Nation Antimicrobial agents and chemotherapy 50 (6), 1953-1958, 2006 | 456 | 2006 |
| Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens AM Sandri, CB Landersdorfer, J Jacob, MM Boniatti, MG Dalarosa, ... Clinical infectious diseases 57 (4), 524-531, 2013 | 442 | 2013 |
| Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus RL Nation, J Li, O Cars, W Couet, MN Dudley, KS Kaye, JW Mouton, ... The Lancet infectious diseases 15 (2), 225-234, 2015 | 382 | 2015 |
| Colistin and polymyxin B: peas in a pod, or chalk and cheese? RL Nation, T Velkov, J Li Clinical infectious diseases 59 (1), 88-94, 2014 | 324 | 2014 |
| In Vitro Pharmacodynamic Properties of Colistin and Colistin Methanesulfonate against Pseudomonas aeruginosaIsolates from Patients with Cystic Fibrosis J Li, J Turnidge, R Milne, RL Nation, K Coulthard Antimicrobial agents and chemotherapy 45 (3), 781-785, 2001 | 323 | 2001 |
| Management of meningitis due to antibiotic-resistant Acinetobacter species BN Kim, AY Peleg, TP Lodise, J Lipman, J Li, R Nation, DL Paterson The Lancet infectious diseases 9 (4), 245-255, 2009 | 303 | 2009 |
| Dosing guidance for intravenous colistin in critically ill patients RL Nation, SM Garonzik, V Thamlikitkul, EJ Giamarellos-Bourboulis, ... Clinical Infectious Diseases 64 (5), 565-571, 2017 | 282 | 2017 |
| Pharmacokinetics of intravenous polymyxin B in critically ill patients AP Zavascki, LZ Goldani, G Cao, SV Superti, L Lutz, AL Barth, F Ramos, ... Clinical infectious diseases 47 (10), 1298-1304, 2008 | 271 | 2008 |
| A secondary mode of action of polymyxins against Gram-negative bacteria involves the inhibition of NADH-quinone oxidoreductase activity ZZ Deris, J Akter, S Sivanesan, KD Roberts, PE Thompson, RL Nation, ... The Journal of antibiotics 67 (2), 147-151, 2014 | 260 | 2014 |
| The disposition of morphine and its 3-and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine RW Milne, RL Nation, AA Somogyi Drug metabolism reviews 28 (3), 345-472, 1996 | 249 | 1996 |
